Europe Breast Cancer Screening Tests Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Europe Breast Cancer Screening Tests Market Analysis by Mordor Intelligence

The Europe Breast Cancer Screening Tests Market size is estimated at USD 0.90 billion in 2025, and is expected to reach USD 1.37 billion by 2030, at a CAGR of 8.68% during the forecast period (2025-2030).

The studied market is anticipated to grow during the projected period owing to the growing incidence of breast cancer, government initiatives for early detection of breast cancer, and a high number of clinical trial developments and technological advancements in tests.

The high burden of breast cancer in Europe is anticipated to propel the demand for breast cancer screening tests during the forecast period. For instance, according to the European Breast Cancer Coalition 2023, breast cancer was the most commonly diagnosed cancer in Europe in 2023, with around 380,000 new cases, primarily among women. This disease represented 13.8% of all cancer diagnoses within the EU. Projections suggest that breast cancer cases will continue to rise, driven by an aging population and certain lifestyle factors. In response, the European Commission, under its Beating Cancer Plan, is intensifying screening programs. Their goal is to achieve a 90% screening rate for eligible populations by 2025, aiming to bolster early detection and treatment outcomes. Thus, the high burden of breast cancer in the European region is expected to accelerate the demand for breast cancer screening tests, thereby propelling the market growth during the forecast period.

Furthermore, the rising clinical trials for the development and evaluation of screening tests are also contributing to the market growth. For instance, as per clinicaltrials.gov, a clinical trial, sponsored by the University Medical Center in Utrecht, Netherlands, is slated for completion by April 2023. This study aims to assess the cost-effectiveness of biennial screenings using both mammography and MRI, in contrast to mammography alone, for women aged 50-75 exhibiting over 75% mammographic density. The high number of clinical trials are expected to create an opportunity for market players to develop advanced screening tests, which are further expected to boost the market growth.

Further, rising government and private organization initiatives to support breast cancer screening in Europe are expected to propel the adoption of breast cancer screening tests, boosting the market growth. For instance, European Society of Radiology (ESR) announced that the European Commission’s Joint Research Centre (JRC), in collaboration with the Directorate General for Health and Food Safety (DG SANTE), has established a new Working Group. This group is tasked with crafting guidelines for breast cancer screening and diagnosis. The initiative seeks to set forth detailed requirements for breast cancer services, covering the entire care pathway. Such guidelines will fuel the adoption of breast cancer diagnostics and is likely to contribute the segment growth over the projected period.

Therefore, owing to the aforementioned factors, such as the high burden of breast cancer, rising clinical trial developments, and government initiatives, the studied market is anticipated to grow over the projected period. However, the high cost of breast cancer screening tests, side effects of radiation during screening tests, and errors in screening are likely to impede the market growth.